Factors of Influence in 2019, Key Indicators and Opportunity within Exelixis, Varian Medical, DXC Technology, Bridgepoint Education, Armstrong World Industries, and Immunomedics — New Research Emphasizes Economic Growth

NEW YORK, Feb. 01, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Exelixis, Inc. (NASDAQ:EXEL), Varian Medical Systems, Inc. (NYSE:VAR), DXC Technology Company. (NYSE:DXC), Bridgepoint Education, Inc. (NYSE:BPI), Armstrong World Industries, Inc. (NYSE:AWI), and Immunomedics, Inc. (NASDAQ:IMMU), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

EXEL DOWNLOAD: http://Capital-Review.com/register/?so=EXEL
VAR DOWNLOAD: http://Capital-Review.com/register/?so=VAR
DXC DOWNLOAD: http://Capital-Review.com/register/?so=DXC
BPI DOWNLOAD: http://Capital-Review.com/register/?so=BPI
AWI DOWNLOAD: http://Capital-Review.com/register/?so=AWI
IMMU DOWNLOAD: http://Capital-Review.com/register/?so=IMMU

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine Exelixis, Inc. (NASDAQ:EXEL), Varian Medical Systems, Inc. (NYSE:VAR), DXC Technology Company. (NYSE:DXC), Bridgepoint Education, Inc. (NYSE:BPI), Armstrong World Industries, Inc. (NYSE:AWI), and Immunomedics, Inc. (NASDAQ:IMMU) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed January 30th, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

EXELIXIS, INC. (EXEL) REPORT OVERVIEW

Exelixis' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Exelixis reported revenue of $225.40MM vs $152.51MM (up 47.79%) and analysts estimated basic earnings per share $0.42 vs $0.28 (up 50.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Exelixis reported revenue of $452.48MM vs $191.45MM (up 136.34%) and analysts estimated basic earnings per share $0.52 vs -$0.28. Analysts expect earnings to be released on February 12th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.12. The estimated EPS forecast for the next fiscal year is $1.23 and is expected to report on February 12th, 2019.

To read the full Exelixis, Inc. (EXEL) report, download it here: http://Capital-Review.com/register/?so=EXEL

-----------------------------------------

VARIAN MEDICAL SYSTEMS, INC. (VAR) REPORT OVERVIEW

Varian Medical's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Varian Medical reported revenue of $801.60MM vs $721.80MM (up 11.06%) and analysts estimated basic earnings per share $1.27 vs $0.85 (up 49.41%). For the twelve months ended September 30th, 2018 vs September 30th, 2017, Varian Medical reported revenue of $2,919.10MM vs $2,619.30MM (up 11.45%) and analysts estimated basic earnings per share $1.64 vs $2.36 (down 30.51%). Analysts expect earnings to be released on April 24th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $1.15. The estimated EPS forecast for the next fiscal year is $5.21 and is expected to report on October 22nd, 2019.

To read the full Varian Medical Systems, Inc. (VAR) report, download it here: http://Capital-Review.com/register/?so=VAR

-----------------------------------------

DXC TECHNOLOGY COMPANY. (DXC) REPORT OVERVIEW

DXC Technology's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, DXC Technology reported revenue of $5,013.00MM vs $5,453.00MM (down 8.07%) and analysts estimated basic earnings per share $0.93 vs $0.90 (up 3.33%). For the twelve months ended March 31st, 2018 vs March 31st, 2017, DXC Technology reported revenue of $24,556.00MM vs $7,607.00MM (up 222.81%) and analysts estimated basic earnings per share $6.15 vs -$0.88. Analysts expect earnings to be released on February 7th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $2.15. The estimated EPS forecast for the next fiscal year is $9.08 and is expected to report on May 23rd, 2019.

To read the full DXC Technology Company. (DXC) report, download it here: http://Capital-Review.com/register/?so=DXC

-----------------------------------------

BRIDGEPOINT EDUCATION, INC. (BPI) REPORT OVERVIEW

Bridgepoint Education's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Bridgepoint Education reported revenue of $114.86MM vs $119.37MM (down 3.78%) and basic earnings per share $0.16 vs $0.00. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Bridgepoint Education reported revenue of $478.40MM vs $527.09MM (down 9.24%) and analysts estimated basic earnings per share $0.33 vs -$0.65. Analysts expect earnings to be released on February 20th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.16. The estimated EPS forecast for the next fiscal year is $0.62 and is expected to report on February 20th, 2019.

To read the full Bridgepoint Education, Inc. (BPI) report, download it here: http://Capital-Review.com/register/?so=BPI

-----------------------------------------

ARMSTRONG WORLD INDUSTRIES, INC. (AWI) REPORT OVERVIEW

Armstrong World Industries' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Armstrong World Industries reported revenue of $260.50MM vs $233.90MM (up 11.37%) and analysts estimated basic earnings per share $1.50 vs $0.93 (up 61.29%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Armstrong World Industries reported revenue of $893.60MM vs $837.30MM (up 6.72%) and analysts estimated basic earnings per share $2.89 vs $1.88 (up 53.72%). Analysts expect earnings to be released on February 25th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was $0.50. The estimated EPS forecast for the next fiscal year is $4.34 and is expected to report on February 25th, 2019.

To read the full Armstrong World Industries, Inc. (AWI) report, download it here: http://Capital-Review.com/register/?so=AWI

-----------------------------------------

IMMUNOMEDICS, INC. (IMMU) REPORT OVERVIEW

Immunomedics' Recent Financial Performance

For the twelve months ended June 30th, 2018 vs June 30th, 2017, Immunomedics reported revenue of $2.16MM vs $3.09MM (down 30.26%) and analysts estimated basic earnings per share -$1.78 vs -$1.47. Analysts expect earnings to be released on February 14th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.19. The estimated EPS forecast for the next fiscal year is -$1.35 and is expected to report on August 22nd, 2019.

To read the full Immunomedics, Inc. (IMMU) report, download it here: http://Capital-Review.com/register/?so=IMMU

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Nicole Garrens, Media Department
Office: +1 (410) 280-7496
E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.